Tigen welcomes Michel Orsinger to the board of directors. As a global leader, Michel will support Tigen’s growth through his extensive healthcare and leadership experience.
As a Swiss citizen with a truly international career and global mindset, Michel Orsinger will complement Tigen’s active board of directors and be a curious and compassionate ally for the Tigen team leveraging his extensive 30 years’ experience and network in pharmaceuticals and medtech.
Michel Orsinger is engaged in various venture capital and private equity companies, including EQT as a healthcare advisor. He is also a Board Member at Takeda Pharmaceuticals. He was the worldwide Chairman Global Orthopedics DePuy Synthes Companies at Johnson & Johnson until 2015. He was the CEO & President of Synthes that was sold to Johnson & Johnson in 2012. Prior to his career at Synthes, he was a Division President for Novartis OTC products. He built his consumer goods palmares at Mars and Procter & Gamble.
Michel Orsinger is excited about the collaboration: “When we started the conversation about the future development of Tigen, I sensed the richness of expertise and ambition to transform the Cell & Gene Ecosystem. I am deeply motivated by the highly qualified team and the purposefulness of Tigen to accelerate access to breakthrough cancer therapies for patients and society. Having seen other sectors being disrupted, I could see the Tigen team having a similar impact on the Cell & Gene industry.”
Emmanuel Savioz, founder and CEO of Tigen is convinced: “Michel Orsinger is a well recognised leader in global healthcare. He will help us further develop our disruptive business model and scale globally. He listens carefully, draws sharp conclusions and connects with his network to support us to achieve our ambitions."